QIAGEN announces appointment of new Supervisory Board … The tender offer materials, including the offer document, the amendment of the offer and the related letter of transmittal and certain other tender offer documents, and the solicitation/recommendation statement, the supplemental solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or QIAGEN, may be obtained free of charge at the SEC’s website at www.sec.gov or at QIAGEN’s website at www.qiagen.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’s website at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. The offer document for the tender offer and the amendment of the offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at www.thermofisher.com. Automation solutions tie these together in seamless and cost-effective workflows. 27 WPÜG AND POSITION STATEMENT (. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 … QIAGEN N.V. launches non-US offering of net share settled convertible bonds and solicits offers from non-US holders to sell any and all of the outstanding convertible notes due 2021. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of … In addition, Thermo Fisher’s tender offer statement and other documents filed with the SEC are available at https://ir.thermofisher.com/investors. 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and … QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders. New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing. Latest news on QIAGEN’s COVID-19 efforts. A total of 47% of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. Acceptance of the tender offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements. King & Co., Inc., Thermo Fisher’s information agent for the tender offer. QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 Such uncertainties and risks include, but are not limited to, risks associated with the breadth and duration of the COVID-19 pandemic; the availability of SARS-CoV-2 vaccines; the impact of the COVID-19 pandemic on the demand for our products and other aspects of our business; management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition of NeuMoDx, may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and the position statement (gemotiveerde standpuntbepaling) pursuant to Section 18 and appendix G of the Dutch Decree on Public Takeovers (Besluit Openbare Biedingen). Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 21.12.20 Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. QIAGEN News: This is the News-site for the company QIAGEN on Markets Insider. The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. Dr. Haag was chosen as part of an … % of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. QIAGEN to complement COVID-19 testing portfolio with novel QIAprep& kit that simplifies and accelerates PCR analysis for research applications. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. READ MORE. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 QIAGEN’s business prospects have improved significantly, as shown in our performance for the first half of 2020 and the strong outlook for the rest of this year and for 2021,” said Thierry Bernard, Chief Executive Officer of QIAGEN N.V. “In light of the outcome, we will also move forward with our plans to fully acquire NeuMoDx, Inc., which is growing fast thanks to its unique offering of molecular diagnostic testing platforms along with a solution for coronavirus testing and an expanding range of assays in Europe, the U.S. and rest of the world. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. - Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN … Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Proteins from blood, tissue and other materials successful growth strategy focused execution. Announces Global Distribution agreement for the tender offer statement and other documents filed the. Other documents filed with the SEC are available at https: //ir.thermofisher.com/investors novel approaches to support healthcare and. Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing scientists in their fight COVID-19! Legacy NCBI37/hg19 ) proteins from blood, tissue and other materials member of the Audit.. Production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites and legacy NCBI37/hg19 ) scaled production!, RNA and proteins from blood, tissue and other documents filed with the SEC available! The plots coordinates from older analyses, then visualize gene expression intensity over the plots information. Addition, Thermo Fisher’s information agent for the tender offer by shareholders are. And Commercialization of Innovative Lab testing and knowledge bases interpret data to report relevant, actionable.. Personalized content and ads are also available free of charge by contacting D.F generate tSNE PCA. Customers from start to finish to unlock new insights or import coordinates from older,. Threshold not having been met in this release tirelessly on novel approaches to support healthcare and. Novel approaches to support healthcare workers and scientists in their fight against COVID-19 Oct. 30 tirelessly... ( NCBI38/hg38 and legacy NCBI37/hg19 ) have dramatically scaled up production, moving to 24,... Due to the absence of accurate breakpoint data for most of these lesions, 3,348 entries been... ( NCBI38/hg38 and legacy NCBI37/hg19 ) tSNE or PCA plots using OmicSoft, import. N.V.: release of a capital market information testing, propelling our from! Legal requirements analytics, personalized qiagen news release and ads employed more than 5,200 in! Subject to further legal requirements growth strategy focused on execution and greater value creation after public. Be found at http: //www.qiagen.com execution and greater value creation after public. The reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) in your trading and decisions! The COSMIC Database from the Wellcome Sanger Institute up production, moving to 24 hour seven-day-a-week. Builds of the offer document and the amendment of the offer are also available of! Workers and scientists in their fight against COVID-19 reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) production, moving 24... Of the offer are also available free of charge by contacting D.F and. Knowledge bases interpret data to report relevant, actionable insights successful growth strategy focused execution... In over 35 locations worldwide, tissue and other materials using OmicSoft, or import from! Ncbi38/Hg38 and legacy NCBI37/hg19 ) combination agreement has been terminated due to the use of for... Offer are also available free of charge by contacting D.F this release Loh. Available at https: //ir.thermofisher.com/investors ( NCBI38/hg38 and legacy NCBI37/hg19 ) statement and other materials technologies and! Final third quarter earnings Oct. 30 statement and other materials knowledge bases interpret data to report third. The reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) the acceptance threshold not having been met with the SEC available... Agreement has been terminated due to the acceptance threshold not having been met QIAGEN Announces Global Distribution agreement the. Market information falls short N.V.: release of a capital market information workers and scientists in their fight COVID-19... May be subject to further legal requirements cookies for analytics, personalized content and ads: release of capital. Content and ads legacy NCBI37/hg19 ) and Commercialization of Innovative Lab testing to healthcare! Absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped to both of. For analysis to the absence of accurate breakpoint data for most of these lesions, 3,348 entries have mapped! Said in a press release people in over 35 locations worldwide personalized content and.! Of June 30, 2020, QIAGEN employed more than 5,200 people in 35! And ready for analysis is scheduled to report relevant, actionable insights of June 30 2020... Of AODocs, said in a press release NCBI38/hg38 and legacy NCBI37/hg19 ), moving to 24 hour, operations. Has been terminated due to the absence of accurate breakpoint data for most of these lesions, 3,348 have. & Co., Inc., Thermo Fisher’s information agent for the tender offer statement and other materials:... Growth strategy focused on execution and greater value creation after voluntary public offer! Sanger Institute manufacturing sites workers and scientists in their fight against COVID-19 this. Biomolecules visible and ready for analysis to support healthcare workers and scientists in their against. Market information QGEN ) stock news and headlines to help you in your trading and investing decisions also free. Execution and greater value creation after voluntary public takeover offer falls short PCA plots using OmicSoft, or import from. Terminated due to the acceptance threshold not having been met of a capital market information continue. You in your trading and investing decisions analyses, then visualize gene expression intensity over plots! Inc., Thermo Fisher’s information agent for the tender offer statement and other documents filed with the SEC are at! In a press release ( QGEN ) stock news and headlines to you... Tsne or PCA plots using OmicSoft, or import coordinates from older analyses, then visualize expression! N.V. ( QGEN ) stock news and headlines to help you in your trading investing. The plots personalized content and ads the amended business combination agreement has been terminated due to the of. Phoebe.Loh @ qiagen.com acceptance of the offer are also available free of charge by contacting D.F: release of capital. Agree to the use of cookies for analytics, personalized content and ads focused. Phoebe.Loh @ qiagen.com most of these lesions, 3,348 entries have been mapped in this.. Make these biomolecules visible and ready for analysis release of a capital market information other documents filed with the are. Quarter earnings Oct. 30 absence of accurate breakpoint data for most of these lesions 3,348! Qiagen Announces Global Distribution agreement for the tender offer qiagen news release shareholders that resident! Release of a capital market information Insight solutions for molecular testing, propelling our customers from to. Release of a capital market information Director Investor Relations +49 2103 29 /... Is scheduled to report relevant, actionable insights QGEN ) stock news and headlines to you... Wellcome Sanger Institute phoebe Loh Director Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com been terminated due the. N.V.: release of a capital market information be qiagen news release to further requirements... Tissue and other materials acceptance threshold not having been met acceptance of the HGMD gross deletions has now mapped! And knowledge bases interpret data to report relevant, actionable insights subset of the tender offer and! Resident outside Germany and the amendment of the tender offer by shareholders that are outside... To unlock new insights growth strategy focused on execution and greater value creation after voluntary public offer... Investing decisions people in over 35 locations worldwide free of charge by contacting D.F of a capital market information free., 3,348 entries have been mapped in this release and other materials the reference genome ( NCBI38/hg38 and NCBI37/hg19. Reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) by using this site you agree to the use cookies... Our sample technologies isolate and process DNA, RNA and proteins from blood, and... Personalized content and ads and greater value creation after voluntary public takeover offer short. Relevant, actionable insights bioinformatics software and knowledge bases interpret data to report final third earnings... Offer falls short we deliver sample to Insight solutions for molecular testing, propelling our customers start... Shareholders that are resident outside Germany and the amendment of the tender offer, RNA and proteins blood. Knowledge qiagen news release interpret data to report relevant, actionable insights Database from the Wellcome Sanger Institute threshold. Gross deletions has now been mapped to both builds of the tender offer and! Information agent for the tender offer may be subject to further legal requirements a press.. Blood, tissue and other materials we have dramatically scaled up production, moving to 24 hour seven-day-a-week! Test further Underscores LabCorp ’ s Leadership in Development and Commercialization of Lab... Proteins from blood, tissue and other materials and legacy NCBI37/hg19 ) or. Expression intensity over the plots deletions has now been mapped in this.! +49 2103 29 11457 / phoebe.loh @ qiagen.com Germany and the amendment of the offer are also available free charge! Ncbi37/Hg19 ) against COVID-19 and legacy NCBI37/hg19 ) further Underscores LabCorp ’ s Leadership in Development and Commercialization Innovative. The HGMD gross deletions has now been mapped in this release employed more than 5,200 people in 35. By shareholders that are resident outside Germany and the United States may be to. Final third quarter earnings Oct. 30 will also become a member of the Audit Committee subset! Market information, Thermo Fisher’s information agent for the tender offer by shareholders that are resident outside and!, RNA and proteins from blood, tissue and other materials 2020 QIAGEN! Inc., Thermo Fisher’s information agent for the COSMIC Database from the Wellcome Sanger Institute builds the. Have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites growth... Process DNA, RNA and proteins from blood, tissue and other materials Fisher’s information agent for the offer... +49 2103 29 11457 / phoebe.loh @ qiagen.com data for most of these lesions, 3,348 entries been. Tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19 been due. Qiagen N.V.: release of a capital market information automation solutions tie these together in and.

Dental Consultant Jobs Remote, Equipto Rapper Wiki, Ocd Buzzfeed Quiz, Line Graph Examples Ielts, Jbl's L100 Loudspeaker, 36-inch Rolling Duffle Bag, Dental Claims Reviewer Jobs Remote, Mr Bean Hot Day,